Orbimed Advisors LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Orbimed Advisors LLC

  • $4.24 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024
BUY
$55.39 - $72.47 $8.31 Million - $10.9 Million
150,000 New
150,000 $8.82 Million
Q3 2023

Nov 14, 2023
BUY
$23.65 - $89.22 $1.83 Million - $6.91 Million
77,500 New
77,500 $2.95 Million
Q1 2019

May 15, 2019
BUY
$12.81 - $19.82 $960,750 - $1.49 Million
75,000 New
75,000 $1.46 Million

Others Institutions Holding APLS

# of Institutions
308
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email